4,6-dimethyl-2-methylsulfanyl-pyrimidine-5-carboxylic acid | 548773-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4,6-dimethyl-2-methylsulfanyl-pyrimidine-5-carboxylic acid
• 英文别名: 4,6-Dimethyl-2-(methylthio)-5-pyrimidinecarboxylic acid；4,6-dimethyl-2-methylsulfanylpyrimidine-5-carboxylic acid
• CAS: 548773-18-8
• 化学式: C₈H₁₀N₂O₂S
• 分子量: 198.246
• InChiKey: NXCJJXAQMREDQM-UHFFFAOYSA-N

物化性质

• 沸点：
  383.9±37.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  88.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4,6-dimethyl-2-methylsulfanyl-pyrimidine-5-carboxylic acid 在 Oxone 作用下， 以 甲醇 、 水 为溶剂， 生成 4,6-Dimethyl-2-methylsulfonylpyrimidine-5-carboxylic acid
  参考文献：
  名称：

  Heterocylic antiviral compounds

  摘要：

  足迹化学受体拮抗剂，特别是根据式(I)的3,7-二氮杂双环[3.3.0]辛烷化合物，其中R1-R3R6c和X1如本文所定义，是足迹化学CCR5受体的拮抗剂，可用于治疗或预防人类免疫缺陷病毒（HIV-1）感染，或治疗艾滋病或ARC。该发明还提供了用于治疗通过CCR5拮抗剂缓解的疾病的方法。该发明包括药物组合物和使用这些化合物治疗通过CCR5受体介导的疾病的方法。

  公开号：

  US20070191335A1
• 作为产物：
  描述：

  二乙酰乙酸乙酯 在 sodium hydroxide 、 sodium ethanolate 、 caesium carbonate 作用下， 以 乙醇 、 乙腈 为溶剂， 生成 4,6-dimethyl-2-methylsulfanyl-pyrimidine-5-carboxylic acid
  参考文献：
  名称：

  Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides

  摘要：

  The synthesis, SAR and biological evaluation of symmetrical amide analogues of our clinical candidate SCH 351125 are described. A series of potent and orally bioavailable CCR5 antagonists containing symmetrical 2,6-dimethyl isonicotinamides and 2, 6-dimethyl pyrimidines amides were generated with enhanced affinity for the CCR5 receptor. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01063-6

文献信息

• Piperazine derivatives useful as CCR5 antagonists
  申请人：Schering Corporation

  公开号：US06391865B1

  公开（公告）日：2002-05-21

  The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  公开了使用CCR5拮抗剂的公式，其中 R是可选择的取代苯基，吡啶基，噻吩基或萘基; R1是氢或烷基; R2是取代苯基，取代杂环基，萘基，芴基，二苯甲基或可选择的取代苯基或杂环基烷基; R3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基，或可选择的取代苯基，苯基烷基，萘基，萘基烷基，杂环基或杂环基烷基; R4，R5和R7是氢或烷基; R6是氢，烷基或烯基; 用于治疗HIV，固体器官移植排斥，移植物宿主病，关节炎，类风湿关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化症的方法，以及包含它们的新化合物，包含它们的药物组合物，以及CCR5拮抗剂与抗HIV治疗中有用的抗病毒剂或与治疗炎症性疾病中有用的药物的组合。
• Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia
  申请人：Blackaby Peter Wesley

  公开号：US20060276655A1

  公开（公告）日：2006-12-07

  The present invention provides compounds of formula I: wherein R 1 is an alkyl, phenyl, heterocyclyl, cycloalkyl, alkoxy, ester, amino or amide group; R 2 is a phenyl, heterocyclyl, alkyl, cycloalkyl or cycloalkylalkyl group; R 3 is an alkyl, cycloalkyl, cycloalkylalkyl, amino or heterocyclyl group; R 4 and R 5 are hydrogen or alkyl or form a cycloalkyl ring; A is O or N; and m is zero or one; as inhibitors of GlyT1 and thus as useful for treating or preventing diseases such as schizophrenia; with the provision of pharmaceutical compositions, first and second medical uses and methods of treatment.

  本发明提供了化合物的结构如下：其中R1为烷基、苯基、杂环烷基、环烷基、烷氧基、酯基、氨基或酰胺基；R2为苯基、杂环烷基、烷基、环烷基或环烷基烷基；R3为烷基、环烷基、环烷基烷基、氨基或杂环烷基；R4和R5为氢或烷基或形成环烷基环；A为氧或氮；m为零或一；作为GlyT1的抑制剂，因此可用于治疗或预防精神分裂症等疾病；并提供了药物组合物、第一和第二医用途以及治疗方法。
• Heterocyclic antiviral compounds
  申请人：Lee Kyung Eun

  公开号：US20060014767A1

  公开（公告）日：2006-01-19

  Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are allieviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

  化学因子受体拮抗剂，尤其是按照公式（I）制备的3,7-二氮杂双环[3.3.0]辛烷类化合物是化学因子CCR5受体的拮抗剂，可用于治疗或预防人类免疫缺陷病毒（HIV）感染，或治疗艾滋病或ARC。发明还提供了用于缓解与CCR5拮抗剂相关的疾病的治疗方法。该发明包括制备公式I化合物的药物组合物和使用这些化合物治疗这些疾病的方法。该发明还包括制备公式I化合物的过程。
• CYCLOHEXANESULFONYL DERIVATIVES AS GLYT1 INHIBITORS TO TREAT SCHIZOPHRENIA
  申请人：Blackaby Wesley Peter

  公开号：US20100029726A1

  公开（公告）日：2010-02-04

  The present invention provides compounds of formula I: wherein R 1 is an alkyl, phenyl, heterocyclyl, cycloalkyl, alkoxy, ester, amino or amide group; R 2 is a phenyl, heterocyclyl, alkyl, cycloalkyl or cycloalkylalkyl group; R 3 is an alkyl, cycloalkyl, cycloalkylalkyl, amino or heterocyclyl group; R 4 and R 5 are hydrogen or alkyl or form a cycloalkyl ring; A is O or N; and m is zero or one; as inhibitors of GlyT1 and thus as useful for treating or preventing diseases such as schizophrenia; with the provision of pharmaceutical compositions, first and second medical uses and methods of treatment.

  本发明提供了如下式I的化合物： 其中， R1是烷基、苯基、杂环基、环烷基、烷氧基、酯基、氨基或酰胺基； R2是苯基、杂环基、烷基、环烷基或环烷基烷基； R3是烷基、环烷基、环烷基烷基、氨基或杂环基； R4和R5是氢、烷基或形成环烷基环； A是O或N； m为零或一。 这些化合物是GlyT1的抑制剂，因此可用于治疗或预防精神分裂症等疾病。同时，还提供了制药组合物、第一和第二医疗用途及治疗方法。
• Alicyclic Heterocyclic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182140A1

  公开（公告）日：2009-07-16

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P 1 and P 2 are CH or N, q and r are 0 to 2, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is —CO—, —SO 2 —, etc., and R 3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR 4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下式子所示的脂环杂环化合物或其药学上可接受的盐： 其中环A为杂环，环B为碳环，杂环等，P1和P2为CH或N，q和r为0至2，X为—NH—，—O—，—CH2—等，Y为—CH2—，—CO—，—SO2—等，Z为—CO—，—SO2—等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基，用作CCR4功能调节剂，用于预防或治疗支气管哮喘，特应性皮炎等。